Immune Checkpoint Therapies for Melanoma.

Authors :: Buchbinder EI
Source :: Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2021 Feb; Vol. 35 (1), pp. 99-109. Date of Electronic Publication: 2020 Oct 26.
Publication Year :: 2021
Abstract: Immunotherapy with immune checkpoint inhibition has dramatically changed the treatment of melanoma. Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 are approved for the treatment of advanced melanoma alone and in combination. In addition, these agents are approved for use in high-risk resected stage III melanoma in the adjuvant setting. Clinical trials testing the combination of immune checkpoint inhibition with other therapies and novel immunotherapies continue. This article reviews the current literature on approved uses of immune checkpoint inhibition in melanoma and discusses ongoing trials and future directions.<br />Competing Interests: Disclosure Dr E.I. Buchbinder received compensation for consulting from BMS, Trieza, Novartis, and Partner Therapeutics. She receives clinical trial support form Eli Lilly, Novartis, BMS, Genentech, and BVD.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)